Key Points
Abu Dhabi's sovereign fund Mubadala Investment Company plans to expand its footprint in the Indian healthcare space..
Mubadala, an investor in India's second largest hospital chain Manipal, is looking for more healthcare deals in the range of $200-500 million (2,000-4,500 crore), according to a senior executive...
"India is a key geography of focus for Mubadala, and we are looking to meaningfully deploy capital across various sectors, including healthcare," Mina Hamoodi, director of life sciences at Mubadala, told ET..
Additionally, there is increasing penetration across income segments driven by provider footprint expansion beyond metro/tier I cities, she said.. Mubadala is active in the UAE healthcare landscape in partnership with medical institutions including Cleveland Clinic, LabCorp and the Imperial College of London.. Mubadala had done a few large buyouts in the healthcare space globally..
"As a responsible investor, and a steward of capital, our overarching mission is to enable greater access to care, and to reduce the cost of care to the system," Hamoodi said.. Mubadala's major healthcare / life sciences investments include China-based contract research organization Novotech, biotech player Giant Biogene; European diagnostics company Inovie; US-based companies PCI Pharma Services, Recursion Pharma, Resilience; and Cleveland Clinic Abu Dhabi..
